

Canadian Clinical Trials Group
2022 Spring Meeting of Participants

GYNECOLOGY

VIRTUAL MEETING

SATURDAY APRIL 30, 2022 – 12:00 P.M. - 3:00 P.M. EST

CO-CHAIRS: MARK CAREY AND STEPHEN WELCH

SENIOR INVESTIGATOR: WENDY PARULEKAR

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To identify and address, through clinical trial and translational research, the disease burden associated with gynaecological malignancies in Canada.
- To identify clinical trial research opportunities within the Canadian Cancer Trials Group
- To integrate current knowledge regarding therapeutics and tumour biology in trial concept development and conduct.
- To apply best practices in clinical trials conduct and analysis to the Canadian Cancer Trials Group research agenda
- To provide a learning and mentoring environment supportive to new investigators

**PRE-CIRCULATED MATERIALS: WORKING GROUP REPORTS, REPORTS FROM CSTB, LIAISONS ECONOMICS, QOL .
REPORT FROM P-ROC COMMITTEE, CCS GRANT**

12:00-12:10 **Welcome and Overview of the Day**
Organizational change / opportunities for engagement

M. CAREY/ S. WELCH

12:10-12:15 **Announcement: Canadian Cancer Society Successful Grant Application**

M. CAREY/ S. WELCH

12:15 – 13:00 **Guest Lecture:**

Topic: Clinical trials in Gyn Cancers: Partners in advancing patient outcomes

DR. ELISE KOHN

- 13:00-13:30 **Ovarian Cancer WG** S. LAU/A. TINKER
- Update on OWG – meetings, concept reviews, improving engagement
 - Ongoing studies
 - a. OV.25 S. LAU/A. TINKER
 - b. OV.26 S. LAU/A. TINKER
 - c. IND240 S. LAU/A. TINKER
 - Concepts under development
 - a. CANACTOR S. LHEUREUX
 - b. NRG GY030 S. LAU/ P.KONSTANTINOPOULOS
 - c. RESOLVE J. Ethier
 - d. PARP-Retreatment A. TINKER
 - Q&A
- 13:30-14:00 **Endometrial Cancer WG Update** J. MCALPINE/K. HAN
- WG priority
 - Ongoing and planned studies
 - a. ENC.1 S. WELCH
 - b. EN.10 TAPER/RAINBO *POLE*mut BLUE J. MCALPINE/K. HAN
 - c. RAINBO MMRd GREEN S. WELCH
 - Q&A
- 14:00-14:30 **Cervical Cancer WG Update** V. SAMOUELIAN/ E. LEUNG
- Ongoing studies
 - a. CX.6/Senticol III V. SAMOUELIAN
 - b. CXC.2/NRG-GY006 E. LEUNG
 - New concept
 - a. STRIVE J. MCALPINE/AMY JAMIESON
 - Update of previously presented studies/concepts
 - a. Locally Advanced Cervix Cancer Strategies E. LEUNG / V.SAMOUELIAN
 - b. Hypofractionation E. Leung
 - c. Surgical Studies V. SAMOUELIAN
 - Q&A
- 14:30-14:40 **Reports from CSTB WG and Liasons from Economics, QOL** J. KWON / I. KONG
- 14:40-14:50 **IND Committee Update** J. ETHIER
- 14:50-15:00 **PMH Consortium Update** A. OZA/S. L'HEUREUX

OVERALL GOAL/OBJECTIVE OF THE LECTURE:

General objectives and background:

Each spring, the Canadian Cancer Trials group (CCTG) holds a national meeting to help organize and plan cancer clinical trials. Ten disease site groups gather for the meeting. This year, as part of our gynecological disease site meeting, we thought it would be interesting to organize an educational lecture to complement our agenda. It would be very interesting and relevant to have an update from Dr. Kohn on the NCI/NCTN/CTEP, recognizing our relationship with NCI/NCTN and the rapid development of novel therapeutics in this era of molecular and precision medicine. The goal is to provide an engaging and enlightening presentation, geared to our gynecologic clinical trials community, to help us better understand the NCI/NCTN and how CCTG can advance our participation and success in clinical trials.

Date and Time: Saturday April 30th, Time: 12:15 PM EST

Speaker: Dr. Elise Kohn

Topic: Clinical trials in Gyn Cancers: Partners in advancing patient outcomes

Learning objectives: The goal of this session is to better understand the organization, workings, processes of NCI/NCTN and the future of Gyn cancer clinical trials.

At the end of the session the participant will:

- 1) *Review the development and structure of NCI/NCTN*
- 2) *Discuss important operational relationships relating to the NCTN.*
- 3) *Review opportunities for CCTG leadership and participation.*
- 4) *Discuss perspectives on the future of Gyn Cancer clinical trials.*

Key questions to consider. These questions may help guide the presentation; however it may not be possible to cover all of them within the allotted time for the talk:

- 1) What are some of the important historical considerations relating to the development of the NCI/NCTN?
- 2) How are trial concepts developed, advanced, and approved through the NCTN?
- 3) What are key funding considerations for the effective conduct of current clinical trials?
- 4) How can we improve clinical trial output to improve patient outcomes and how can CCTG play a larger role in this?